APREA THERAPEUTICS INC (APRE) Stock Fundamental Analysis

NASDAQ:APRE • US03836J2015

0.7863 USD
+0.06 (+8.01%)
Last: Feb 19, 2026, 10:46 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to APRE. APRE was compared to 521 industry peers in the Biotechnology industry. While APRE seems to be doing ok healthwise, there are quite some concerns on its profitability. APRE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • APRE had negative earnings in the past year.
  • APRE had a negative operating cash flow in the past year.
  • In the past 5 years APRE always reported negative net income.
  • APRE had a negative operating cash flow in each of the past 5 years.
APRE Yearly Net Income VS EBIT VS OCF VS FCFAPRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -91.04%, APRE is doing worse than 72.74% of the companies in the same industry.
  • APRE has a Return On Equity of -112.02%. This is comparable to the rest of the industry: APRE outperforms 42.61% of its industry peers.
Industry RankSector Rank
ROA -91.04%
ROE -112.02%
ROIC N/A
ROA(3y)-163.39%
ROA(5y)-122.63%
ROE(3y)-186.11%
ROE(5y)-140.49%
ROIC(3y)N/A
ROIC(5y)N/A
APRE Yearly ROA, ROE, ROICAPRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • APRE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APRE Yearly Profit, Operating, Gross MarginsAPRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K -2.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • APRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for APRE has been increased compared to 1 year ago.
  • APRE has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for APRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
APRE Yearly Shares OutstandingAPRE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
APRE Yearly Total Debt VS Total AssetsAPRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • APRE has an Altman-Z score of -34.48. This is a bad value and indicates that APRE is not financially healthy and even has some risk of bankruptcy.
  • APRE has a Altman-Z score of -34.48. This is amonst the worse of the industry: APRE underperforms 89.06% of its industry peers.
  • APRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.48
ROIC/WACCN/A
WACC8.69%
APRE Yearly LT Debt VS Equity VS FCFAPRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 5.20 indicates that APRE has no problem at all paying its short term obligations.
  • APRE's Current ratio of 5.20 is in line compared to the rest of the industry. APRE outperforms 57.77% of its industry peers.
  • APRE has a Quick Ratio of 5.20. This indicates that APRE is financially healthy and has no problem in meeting its short term obligations.
  • APRE has a Quick ratio (5.20) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.2
Quick Ratio 5.2
APRE Yearly Current Assets VS Current LiabilitesAPRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.35% over the past year.
  • The Revenue for APRE has decreased by -62.75% in the past year. This is quite bad
EPS 1Y (TTM)40.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.56%
Revenue 1Y (TTM)-62.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.44%

3.2 Future

  • APRE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.08% yearly.
  • The Revenue is expected to grow by 105.20% on average over the next years. This is a very strong growth
EPS Next Y32.81%
EPS Next 2Y24.27%
EPS Next 3Y20.87%
EPS Next 5Y18.08%
Revenue Next Year-78.54%
Revenue Next 2Y-72.67%
Revenue Next 3Y145.58%
Revenue Next 5Y105.21%

3.3 Evolution

APRE Yearly Revenue VS EstimatesAPRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
APRE Yearly EPS VS EstimatesAPRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for APRE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APRE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APRE Price Earnings VS Forward Price EarningsAPRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APRE Per share dataAPRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • APRE's earnings are expected to grow with 20.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.27%
EPS Next 3Y20.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for APRE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

APREA THERAPEUTICS INC

NASDAQ:APRE (2/19/2026, 10:46:59 AM)

0.7863

+0.06 (+8.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-23
Inst Owners19.63%
Inst Owner Change-5.87%
Ins Owners21.66%
Ins Owner Change0.84%
Market Cap5.50M
Revenue(TTM)488.30K
Net Income(TTM)-13.04M
Analysts84.44
Price Target6.8 (764.81%)
Short Float %4.89%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.94%
Min EPS beat(2)-36.13%
Max EPS beat(2)30.25%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-23.08%
PT rev (3m)-36.51%
EPS NQ rev (1m)-10.38%
EPS NQ rev (3m)-13.04%
EPS NY rev (1m)5.81%
EPS NY rev (3m)-3.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.26
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 0.47
EV/EBITDA N/A
EPS(TTM)-2.38
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-1.93
FCFYN/A
OCF(TTM)-1.93
OCFYN/A
SpS0.07
BVpS1.67
TBVpS1.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -91.04%
ROE -112.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-163.39%
ROA(5y)-122.63%
ROE(3y)-186.11%
ROE(5y)-140.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.2
Quick Ratio 5.2
Altman-Z -34.48
F-Score1
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.56%
EPS Next Y32.81%
EPS Next 2Y24.27%
EPS Next 3Y20.87%
EPS Next 5Y18.08%
Revenue 1Y (TTM)-62.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.44%
Revenue Next Year-78.54%
Revenue Next 2Y-72.67%
Revenue Next 3Y145.58%
Revenue Next 5Y105.21%
EBIT growth 1Y6.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.71%
EBIT Next 3Y-4.7%
EBIT Next 5Y-10.25%
FCF growth 1Y-7.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.27%
OCF growth 3YN/A
OCF growth 5YN/A

APREA THERAPEUTICS INC / APRE FAQ

Can you provide the ChartMill fundamental rating for APREA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to APRE.


What is the valuation status of APREA THERAPEUTICS INC (APRE) stock?

ChartMill assigns a valuation rating of 1 / 10 to APREA THERAPEUTICS INC (APRE). This can be considered as Overvalued.


How profitable is APREA THERAPEUTICS INC (APRE) stock?

APREA THERAPEUTICS INC (APRE) has a profitability rating of 0 / 10.